A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.
about
Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysisOncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinomaAre VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewGoing into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies.Axitinib for the treatment of advanced non-small-cell lung cancer.Nintedanib in non-small cell lung cancer: from preclinical to approval.Sorafenib: 10 years after the first pivotal trial.Anti-angiogenesis in Personalized Therapy of Lung Cancer.Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations.Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.Strategies targeting angiogenesis in advanced non-small cell lung cancer.Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one?The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non-small cell lung cancer cells.Clinical response to apatinib monotherapy in advanced non-small cell lung cancer.Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.Efficacy of opioids versus placebo in chronic pain: a systematic review and meta-analysis of enriched enrollment randomized withdrawal trials.Antiangiogenic therapies in non-small-cell lung cancer.
P2860
Q27003304-AF91AFDE-B564-408A-A514-AC43B196E2ABQ27852873-E2C3E0A6-033B-4599-8DB5-138D710D910CQ28085104-666E576B-EBFD-4DB0-8B90-A585A7DC3D05Q33418555-D547771C-9C2A-432B-97AA-A71AB08CA1A8Q33633424-510F5BB7-77B1-4A22-BD9B-60197E7DC837Q36070099-CCC151AC-A707-48A3-8244-7982D5C65DA9Q36270115-FD3CB192-1FBE-4010-B531-8ED9D1BE257AQ37583786-E66F7E91-58BD-4124-A642-62CC6EC824BAQ38085684-3F82C004-AD06-464B-8243-81CE3187968AQ38412048-04743C16-B4AA-452A-804F-60DD0BB83C6EQ38544841-02D27196-4D79-4933-A0C8-7D9C76E9DCA0Q38669276-A3604C04-43B4-42CC-A53F-DDDA51D00AE9Q38936376-612D37E5-EA61-4369-8BB9-9CCDA29B5EC7Q38964908-0C373D20-0574-4A29-8EF8-B6C0072947C7Q41593429-9C852D1C-AD0E-475D-8B5C-3D4075EDA81EQ41867909-EB03FE72-A173-49A0-A6D0-408E5CE7DE3AQ42382909-72C323E3-7493-4C58-85D0-E933DC28748AQ43298298-EC1AB527-3374-457D-88AB-70090D4222E5Q47305390-06E24148-4DA9-4345-A6FA-74A2BC87E54EQ48223594-43EB00B6-4D15-4632-8FB5-2563F2112D46Q54996859-D8BC4A1C-4EC7-4D58-9395-165051720EBFQ55168137-F54768A2-517B-4F00-8CBA-F96BCB5E403F
P2860
A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A double-blind randomized disc ...... ve oncology group study E2501.
@ast
A double-blind randomized disc ...... ve oncology group study E2501.
@en
type
label
A double-blind randomized disc ...... ve oncology group study E2501.
@ast
A double-blind randomized disc ...... ve oncology group study E2501.
@en
prefLabel
A double-blind randomized disc ...... ve oncology group study E2501.
@ast
A double-blind randomized disc ...... ve oncology group study E2501.
@en
P2093
P2860
P1476
A double-blind randomized disc ...... ve oncology group study E2501.
@en
P2093
Anne M Traynor
David P Carbone
Heather A Wakelee
Joan H Schiller
Ju-Whei Lee
Nasser H Hanna
P2860
P304
P356
10.1097/JTO.0B013E31826149BA
P577
2012-10-01T00:00:00Z